Drug intelligence / Profile preview

KRAS mutation-specific TCR-T cell therapy

Development stage: Preclinical
Lead developer: Alaunos Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KRAS mutation-specific TCR-T cell therapy is an investigational cell therapy developed by Alaunos Therapeutics in collaboration with the National Cancer Institute (NCI). This therapy utilizes Alaunos's proprietary non-viral Sleeping Beauty gene transfer technology to engineer T-cells. These engineered T-cells are designed to specifically target tumor-specific hotspot mutations in the KRAS gene, aiming to induce an immune response against cancer cells. Clinical data has shown an objective clinical response in patients with advanced non-small cell lung cancer.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on KRAS mutation-specific TCR-T cell therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRAS mutation-specific TCR-T cell therapy.

Explore the full profile